Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript Affimed N.V. (NASDAQ:AFMD ) Q1 2024 Earnings Conference Call June 12, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head, IR Andreas Harstrick – CMO and Interim CEO Michael Wolf – VP, Finance Conference Call Participants Srikripa Devarakonda - Truist Securities Daina Graybosch - Leerink Partners Maury Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Company Bradley Canino - Stifel, Nicolaus & Company Operator Good day, everyone and welcome to Affimed's First Quarter 2024 Earnings and Corporate Update Call.
Affimed Reports First Quarter 2024 Financial Results & Business Update - Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024 MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year? Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.
Affimed''s AFM24 With Atezolizumab For EGFR Wild-Type NSCLC Gets FDA Fast Track Status; Stock Up Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, Wednesday announced that it has received Fast Track Designation from the U.S. Food and Drug Administration for combination therapy of AFM24 with Atezolizumab for EGFR Wild-Type non-small cell lung cancer or NSCLC.
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a study The FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 study Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need Company to host a conference call / webcast on June 1, 2024 at 7:00 p.m. EDT to discuss the updated data from the AFM24-102 trial MANNHEIM, Germany, May 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V.
Affimed Announces Annual General Meeting of Shareholders MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 26, 2024 at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands.